|
|
|
| Development and Clinical Progress of mRNA Vaccine |
HU Shun1,2,3,4,YI You-jin1,*( ),HU Tao3,LI Fu-sheng2,* |
1 College of Food Science and Technology, Hunan Agricultural University, Changsha 410128, China
2 Kangzhong (Beijing) Biotechnology Co., Ltd., Beijing 100176, China; Institute of Process Engineering, Chinese Academy of Sciences, Beijing 100190, China; School of Public Healthy, Xiangnan University, Chenzhou 423000, China |
|
|
|
Abstract As the increasingly develepoment of mRNA stability and delivery systems, the mRNA vaccine has made rapid progress in the individualized tumor vaccine in recent years. Due to its simple production process, expression the antigens in cells, and security features is superior to DNA vaccine, mRNA is a new form of vaccine promising alternative to attenuated and inactivated vaccine and protein vaccine.In order to understand the development and research status of global mRNA vaccine, the molecular design, delivery system and clinical research status of mRNA vaccine were analyzed and summarized, providing reference for the subsequent development and research of mRNA vaccine.
|
|
Received: 04 March 2019
Published: 17 December 2019
|
|
|
|
Corresponding Authors:
You-jin YI,Fu-sheng LI
E-mail: yiyoujin@163.com
|
|
|
| [1] |
Wolff J A, Malone R W, Williams P , et al. Direct gene transfer into mouse muscle in vivo. Science, 1990,247(4949):1465-1468.
doi: 10.1038/s41434-019-0106-3
pmid: 31624368
|
|
|
| [2] |
Sahin U, Derhovanessian E, Miller M , et al. Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer. Nature, 2017,547(7662):222-226.
doi: 10.1038/nature23003
pmid: 28678784
|
|
|
| [3] |
Kormann M S D, Hasenpusch G, Aneja M K , et al. Expression of therapeutic proteins after delivery of chemically modified mRNA in mice. Nature Biotechnology, 2011,29(2):154-157.
doi: 10.1038/nbt.1733
pmid: 21217696
|
|
|
| [4] |
Peng Z H, Sharma V, Singleton S F , et al. Synjournal and application of a chain-terminating dinucleotide mRNA cap analog. Organic Letters, 2002,4(2):161-164.
doi: 10.1021/ol0167715
pmid: 11796040
|
|
|
| [5] |
Stepinski J, Waddell C, Stolarski R , et al. Synjournal and properties of mRNAs containing the novel “anti-reverse” cap analogues 7-methyl(3-O-methyl)GpppG and 7-methyl(3-deoxy)GpppG. RNA, 2001,7(10):1486-1495.
pmid: 11680853
|
|
|
| [6] |
Jemielity J, Fowler T, Zuberek J , et al. Novel “Anti-Reverse” cap analogues with superior translational properties. RNA, 2003,9(9):1108-1122.
doi: 10.1261/rna.5430403
pmid: 12923259
|
|
|
| [7] |
Grudzien-Nogalska E, Stepinski J, Jemielity J , et al. Synjournal of anti-reverse cap analogs (ARCAs)and their applications in mRNA translation and stability. Methods in Enzymology, 2007,431:203-227.
doi: 10.1016/S0076-6879(07)31011-2
pmid: 17923237
|
|
|
| [8] |
Kuhn A N, Diken M, Kreiter S , et al. Phosphorothioate cap analogs increase stability and translational effciency of RNA vaccines in immature dendritic cells and induce superior immune responses in vivo. Gene Therapy, 2010,17(8):961-971.
doi: 10.1038/gt.2010.52
pmid: 20410931
|
|
|
| [9] |
Kore A R, Shanmugasundaram M, Charles I , et al. Locked nucleic acid (LNA)-modified dinucleotide mRNA cap analogue: synjournal, enzymatic incorporation, and utilization. Journal of the American Chemical Society, 2009,131(18):6364-6365.
doi: 10.1021/ja901655p
pmid: 19385620
|
|
|
| [10] |
Grudzien E, Stepinski J, Jankowska-Anyszka M , et al. Novel cap analogs for in vitro synjournal of mRNAs with high translational efficiency. RNA, 2004,10(9):1479-1487.
doi: 10.1261/rna.7380904
pmid: 15317978
|
|
|
| [11] |
Gray N K, Wickens M . Control of translation initiation in animals. Annual Review of Cell and Developmental Biology, 1998,14(1):399-458.
doi: 10.16288/j.yczz.19-045
pmid: 31624057
|
|
|
| [12] |
Kozak M . At least six nucleotides preceding the AUG initiator codon enhance translation in mammalian cells. Journal of Molecular Biology, 1987,196(4):947-950.
doi: 10.1016/0022-2836(87)90418-9
pmid: 3681984
|
|
|
| [13] |
Pelletier J, Sonenberg N . Insertion mutagenesis to increase secondary structure within the 5' noncoding region of a eukaryotic mRNA reduces translational efficiency. Cell, 1985,40(3):515-526.
doi: 10.1016/0092-8674(85)90200-4
pmid: 2982496
|
|
|
| [14] |
Chen C Y, Shyu A B . AU-rich elements: characterization and importance in mRNA degradation. Trends in Biochemical Sciences, 1995,20(11):465-470.
doi: 10.1016/s0968-0004(00)89102-1
pmid: 8578590
|
|
|
| [15] |
Murray E L, Schoenberg D R . A + U-rich instability elements differentially activate 5'-3' and 3'-5' mRNA decay. Molecular and Cellular Biology, 2007,27(8):2791-2799.
doi: 10.1128/MCB.01445-06
pmid: 17296726
|
|
|
| [16] |
Vlasova-St L I, Bohjanen P R . Coordinate regulation of mRNA decay networks by GU-rich elements and CELF1. Current Opinion in Genetics & Development, 2011,21(4):444-451.
doi: 10.1016/j.pathol.2019.09.008
pmid: 31735344
|
|
|
| [17] |
Sahin U, Holtkamp S, Türecl ? , et al. Modification of RNA, producing an increased transcript stability and translation efficiency: US, US2019/0062762 A1. 2019-2-28[2019-03-01]. .
|
|
|
| [18] |
Ferizi M, Leonhardt C, Meggle C , et al. Stability analysis of chemically modified mRNA using micropattern-based single-cell arrays. Lab on a Chip, 2015,15(17):3561-3571.
doi: 10.1039/c5lc00749f
pmid: 26201602
|
|
|
| [19] |
Wang Z, Kiledjian M . The poly(A)-binding protein and an mRNA stability protein jointly regulate an endoribonuclease activity. Molecular and Cellular Biology, 2000,20(17):6334-6341.
doi: 10.1128/mcb.20.17.6334-6341.2000
pmid: 10938110
|
|
|
| [20] |
Van der Velden A W, Voorma H O , Thomas A A. Vector design for optimal protein expression. Biotechniques, 2001, 31(3):572, 574, 576-580.
doi: 10.1007/s12033-019-00218-x
pmid: 31664704
|
|
|
| [21] |
Alexopoulou L, Holt A C, Medzhitov R , et al. Recognition of double-stranded RNA and activation of NF-κB by Toll-like receptor 3. Nature, 2001,413(6857):732-738.
doi: 10.1038/35099560
pmid: 11607032
|
|
|
| [22] |
Diebold S S, Kaisho T, Hemmi H , et al. Innate antiviral responses by means of TLR7-mediated recognition of single-stranded RNA. Science, 2004,303(5663):1529-1531.
doi: 10.1126/science.1093616
pmid: 14976261
|
|
|
| [23] |
Heil F, Hemmi H, Hochrein H , et al. Species-specifc recognition of single-stranded RNA via Toll-like receptor 7 and 8. Science, 2004,303(5663):1526-1529.
doi: 10.1126/science.1093620
pmid: 14976262
|
|
|
| [24] |
Karikó K, Buckstein M, Ni H , et al. Suppression of RNA recognition by Toll-like receptors: the impact of nucleoside modification and the evolutionary origin of RNA. Immunity, 2005,23(2):165-175.
doi: 10.1016/j.immuni.2005.06.008
pmid: 16111635
|
|
|
| [25] |
Pardi N, Parkhouse K, Kirkpatrick E , et al. Nucleoside-modified mRNA immunization elicits influenza virus hemagglutinin stalk-specific antibodies. Nature Communications, 2018,9(1):3361.
doi: 10.1038/s41467-018-05482-0
pmid: 30135514
|
|
|
| [26] |
Pardi ,N, Parkhouse K,Kirkpatrick E, , et al. Zika virus protection by a single low-dose nucleoside-modified mRNA vaccination. Nature, 2017,543(7644):248-251.
doi: 10.1038/nature21428
pmid: 28151488
|
|
|
| [27] |
Thess A, Grund S, Mui B L , et al. Sequence-engineered mRNA without chemical nucleoside modifications enables an effective protein therapy in large animals. Molecular Therapy, 2015,23(9):1456-1464.
doi: 10.1038/mt.2015.103
pmid: 26050989
|
|
|
| [28] |
Karikó K, Muramatsu H, Welsh F A , et al. Incorporation of pseudouridine into mRNA yields superior nonimmunogenic vector with increased translational capacity and biological stability. Molecular Therapy, 2008,16(11):1833-1840.
doi: 10.1038/mt.2008.200
pmid: 18797453
|
|
|
| [29] |
Kormann M S, Hasenpusch G, Aneja M K , et al. Expression of therapeutic proteins after delivery of chemically modified mRNA in mice. Nature Biotechnology, 2011,29(2):154-157.
doi: 10.1038/nbt.1733
pmid: 21217696
|
|
|
| [30] |
Mays L E, Ammon Treiber S, Mothes B , et al. Modified Foxp3 mRNA protects against asthma through an IL-10-dependent mechanism. Journal of Clinical Investigation, 2013,123(3):1216-1228.
doi: 10.1172/JCI65351
|
|
|
| [31] |
Sahin U, Karikó K , Türeci ?. mRNA-based therapeutics-developing a new class of drugs. Nature Reviews Drug Discovery, 2014,13(10):759-780.
doi: 10.1038/nrd4278
|
|
|
| [32] |
Heiser A, Coleman D, Dannull J , et al. Autologous dendritic cells transfected with prostate-specific antigen RNA stimulate CTL responses against metastatic prostate tumors. Journal of Clinical Investigation, 2002,109(3):409-417.
doi: 10.1172/JCI14364
pmid: 11828001
|
|
|
| [33] |
Rejman J, Oberle V, Zuhorn I S , et al. Size-dependent internalization of particles via the pathways of clathrin- and caveolae-mediated endocytosis. Biochemical Journal, 2004,377(1):159-169.
doi: 10.1016/j.imbio.2014.06.002
pmid: 25082708
|
|
|
| [34] |
Ma Z, Li J, He F , et al. Cationic lipids enhance siRNA-mediated interferon response in mice. Biochemical and Biophysical Research Communications, 2005,330(3):755-759.
doi: 10.1016/j.bbrc.2005.03.041
pmid: 15809061
|
|
|
| [35] |
Landesman-Milo D, Peer D . Toxicity profiling of several common RNAi-based nanomedicines: a comparative study. Drug Delivery and Translational Research, 2014,4(1):96-103.
doi: 10.1007/s13346-013-0158-7
pmid: 25786620
|
|
|
| [36] |
Islam M A ,Reesor E K G,Xu Y, et al. Biomaterials for mRNA delivery. Biomaterials Science, 2015,3(12):1519-1533.
doi: 10.1039/c5bm00198f
pmid: 26280625
|
|
|
| [37] |
Maier M A, Jayaraman M, Matsuda S , et al. Biodegradable lipids enabling rapidly eliminated lipid nanoparticles for systemic delivery of RNAi therapeutics. Molecular Therapy, 2013,21(8):1570-1578.
doi: 10.1038/mt.2013.124
|
|
|
| [38] |
Jayaraman M, Ansell S M, Mui B L , et al. Maximizing the potency of siRNA lipid nanoparticles for hepatic gene silencing in vivo. Angewandte Chemie International Edition. 2012,124(34):8529-8533.
doi: 10.1002/anie.201203263
pmid: 22782619
|
|
|
| [39] |
Pardi N, Tuyishime S, Muramatsu H , et al. Expression kinetics of nucleoside-modified mRNA delivered in lipid nanoparticles to mice by various routes. Journal of Controlled Release, 2015,217:345-351.
doi: 10.1016/j.jconrel.2015.08.007
pmid: 26264835
|
|
|
| [40] |
Sedic M, Senn J J, Lynn A , et al. Safety evaluation of lipid nanoparticle-formulated modified mRNA in the Sprague-Dawley rat and cynomolgus monkey. Veterinary Pathology, 2017,55(2):341-354.
doi: 10.1177/0300985817738095
pmid: 29191134
|
|
|
| [41] |
Rizk M, Tüzmen S X . Update on the clinical utility of an RNA interference-based treatment: focus on Patisiran. Pharmacogenomics and Personalized Medicine, 2017,2017(10):267-278.
doi: 10.2147/PGPM.S87945
pmid: 29184431
|
|
|
| [42] |
Zhao M, Li M, Zhang Z , et al. Induction of HIV-1 gag specific immune responses by cationic micelles mediated delivery of gag mRNA. Drug Delivery, 2016,23(7):2596-2607.
doi: 10.3109/10717544.2015.1038856
pmid: 26024387
|
|
|
| [43] |
Li M, Zhao M, Fu Y , et al. Enhanced intranasal delivery of mRNA vaccine by overcoming the nasal epithelial barrier viaintra- and paracellular pathways. Journal of Controlled Release, 2016,228:9-19.
doi: 10.1016/j.jconrel.2016.02.043
pmid: 26941035
|
|
|
| [44] |
Dong Y, Dorkin J R, Wang W , et al. Poly ( glycoamidoamine ) brushes formulated nanomaterials for systemic siRNA and mRNA delivery in vivo. Nano Letters, 2016,16(2):842-848.
doi: 10.1021/acs.nanolett.5b02428
pmid: 26727632
|
|
|
| [45] |
Prieve M G, Harvie P, Monahan S D , et al. Targeted mRNA therapy for ornithine transcarbamylase deficiency. Molecular Therapy, 2018,26(3):801-813.
doi: 10.1016/j.ymthe.2017.12.024
pmid: 29433939
|
|
|
| [46] |
Gandhi R T, Kwon D S, Macklin E A , et al. Immunization of HIV-1-infected persons with autologous dendritic cells transfected with mRNA encoding HIV-1 gag and Nef. Journal of Acquired Immune Deficiency Syndromes, 2016,71(3):246-253.
doi: 10.1097/QAI.0000000000000852
pmid: 26379068
|
|
|
| [47] |
Kyte J A, Kvalheim G, Lislerud K , et al. T cell responses in melanoma patients after vaccination with tumor-mRNA transfected dendritic cells. Cancer Immunology, Immunotherapy, 2006,56(5):659-675.
doi: 10.1007/s00262-006-0222-y
pmid: 16947019
|
|
|
| [48] |
Kyte J A, Mu L, Aamdal S , et al. Phase I/II trial of melanoma therapy with dendritic cells transfected with autologous tumor-mRNA. Cancer Gene Therapy, 2006,13(10):905-918.
doi: 10.1038/sj.cgt.7700961
pmid: 16710345
|
|
|
| [49] |
Weide B ,Pascolo, S, Scheel B, et al. Direct Injection of protamine-protected mRNA: Results of a phase 1/2 vaccination trial in metastatic melanoma patients. Journal of Immunotherapy, 2009,32(5):498-507.
doi: 10.1097/CJI.0b013e3181a00068
pmid: 19609242
|
|
|
| [50] |
Wilgenhof S, Van Nuffel A M T, Benteyn D,et al. A phase IB study on intravenous synthetic mRNA electroporated dendritic cell immunotherapy in pretreated advanced melanoma patients. Annals of Oncology, 2013,24(10):2686-2693.
doi: 10.1093/annonc/mdt245
|
|
|
| [51] |
Gan L M, Lagerstr?m Fermér M, Carlsson L G , et al. Intradermal delivery of modified mRNA encoding VEGF-A in patients with type 2 diabetes. Nature Communications, 2019,10(1):871.
doi: 10.1038/s41467-019-08852-4
pmid: 30787295
|
|
|
|
Viewed |
|
|
|
Full text
|
|
|
|
|
Abstract
|
|
|
|
|
Cited |
|
|
|
|
| |
Shared |
|
|
|
|
| |
Discussed |
|
|
|
|
